Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$76.19 USD

76.19
6,373,924

-0.57 (-0.74%)

Updated Jun 17, 2024 04:00 PM ET

After-Market: $75.19 -1.00 (-1.31%) 4:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (139 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BSX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Boston Scientific Corporation [BSX]

Reports for Purchase

Showing records 501 - 512 ( 512 total )

Company: Boston Scientific Corporation

Industry: Medical - Products

Record: 501

06/16/2010

Company Report

Pages: 9

Lowering Price Target to Keep Pace with Eroding Med Device Group Multiples Maintaining Below-Consensus Projections, See Ongoing Risk to Street Expectations.

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Company: Boston Scientific Corporation

Industry: Medical - Products

Record: 502

04/28/2010

Company Report

Pages: 2

Weaker guidance, more issues than just ICD''s

Provider: G.RESEARCH, LLC

Analyst: JONAS J

Price: 10.00

Research Provided by a Third Party

Company: Boston Scientific Corporation

Industry: Medical - Products

Record: 503

04/27/2010

Company Report

Pages: 7

Once Again, the Quarterly Refrain: BSX?s Financial Outlook is Greatly Diminished -Still More Downside Risk

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Company: Boston Scientific Corporation

Industry: Medical - Products

Record: 504

04/26/2010

Company Report

Pages: 6

Getting a Lot Worse Before It Can Possibly Get Better - Q1 Weak as Expected, Full-Year Outlook Comes Way Down

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Company: Boston Scientific Corporation

Industry: Medical - Products

Record: 505

04/20/2010

Daily Note

Pages: 22

Med Tech Review and Preview: Big Players Navigate Through Maturing Markets, While BSX Woes

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 75.00

Research Provided by a Third Party

Company: Boston Scientific Corporation

Industry: Medical - Products

Record: 506

03/04/2010

Company Report

Pages: 8

Price: 24.95

Company: Boston Scientific Corporation

Industry: Medical - Products

Record: 507

02/12/2010

Company Report

Pages: 2

Growing Challenges in 2010, downgrading to Hold

Provider: G.RESEARCH, LLC

Analyst: JONAS J

Price: 10.00

Research Provided by a Third Party

Company: Boston Scientific Corporation

Industry: Medical - Products

Record: 508

02/11/2010

Company Report

Pages: 7

2010 Forecasts Now Look a Lot More Reasonable, but Downside Risks Linger Due to Competitive and Pricing Pressures in CRM and DES; Lowering Price Target to $7

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Boston Scientific Corporation

Industry: Medical - Products

Record: 509

02/10/2010

Company Report

Pages: 6

Q4 Results on Target; Guides 2010 Sales a Bit Light, EPS Numbers Down; Announces Restructuring Efforts to Cut $200-$250mm Over 2 Years; WSJ Cries ICD Design Flaw

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Boston Scientific Corporation

Industry: Medical - Products

Record: 510

02/01/2010

Company Report

Pages: 6

$1.725 Billion JNJ Patent Payment Wipes Out Cash Balance Plus Two Quarters of Cash Flows; Eradicates Near-Term Strategic Options - Likely to Force More Cutbacks

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Boston Scientific Corporation

Industry: Medical - Products

Record: 511

01/20/2010

Daily Note

Pages: 17

December Quarter Review and 2010 Preview: The Graying of the Cardiac Devices Market

Provider: WEDBUSH SECURITIES INC.

Price: 50.00

Research Provided by a Third Party

Company: Boston Scientific Corporation

Industry: Medical - Products

Record: 512

01/11/2010

Company Report

Pages: 8

Lowering 2010 Estimates Due to Latest Challenges for TAXUS Drug-Eluting Stent Franchise, Broader Interventional Cardiology Business

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party